Literature DB >> 7523051

Pharmacokinetics of polyvalent proteinase inhibitor (aprotinin) in eye tissues.

N B Chesnokova1, T P Kuznetsova, N E Sosulina.   

Abstract

Drugs having as their active substance aprotinin (trasylol, gordox, etc.) are widely indicated in the treatment of eye pathologies having as their basis an enhanced proteolytic enzyme activation. Our studies have exposed a decrease in proteolytic activity in both eye tissues and tear fluid in response to Gordox administration. Up to date there are no works concerning pharmacokinetics of aprotinin in the eye tissues. The aim of this work was to study the pharmacokinetics of 125I-aprotinin in rabbit eye tissues after instillation. A presence of the substance was registered in the cornea, aqueous humor, and ciliary body within a period of 10-90 minutes after administration, but not in other tissues. Calculation of the pharmacokinetic parameters of aprotinin penetration in the eye showed that its mean residence time in the cornea, aqueous humor and ciliary body was 50-60 min. The addition of polyvinyl alcohol to the instillation solution increased the level of the substance in the tissues, but did not change its mean residence time. The medicine should be instilled every 1-1.5 hrs to support high and stable levels of aprotinin in the eye.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523051     DOI: 10.1007/bf01664935

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  17 in total

1.  [A new treatment concept for severe caustic and thermal burns of the eyes].

Authors:  M Reim
Journal:  Klin Monbl Augenheilkd       Date:  1990-01       Impact factor: 0.700

Review 2.  Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs.

Authors:  H Fritz; G Wunderer
Journal:  Arzneimittelforschung       Date:  1983

3.  [Biochemical basis for using proteolysis inhibitors in inflammatory processes of the cornea].

Authors:  N B Chesnokova; B S Kasavina; A I Shchipanova
Journal:  Vestn Oftalmol       Date:  1983 Jan-Feb

4.  Ulceration is correlated with degradation of fibrin and fibronectin at the corneal surface.

Authors:  M Berman; E Manseau; M Law; D Aiken
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-10       Impact factor: 4.799

5.  Evidence for a role of the plasminogen activator--plasmin system in corneal ulceration.

Authors:  M Berman; R Leary; J Gage
Journal:  Invest Ophthalmol Vis Sci       Date:  1980-10       Impact factor: 4.799

6.  Plasminogen activator activity and plasminogen independent amidolytic activity in tear fluid from healthy persons and patients with anterior segment inflammation.

Authors:  J Tözsér; A Berta; M Punyiczki
Journal:  Clin Chim Acta       Date:  1989-08-31       Impact factor: 3.786

7.  Plasminogen activator and its inhibitor in the experimental corneal wound.

Authors:  T Tervo; K Tervo; G B van Setten; I Virtanen; A Tarkkanen
Journal:  Exp Eye Res       Date:  1989-03       Impact factor: 3.467

8.  Contact lens wear is associated with the appearance of plasmin in the tear fluid--preliminary results.

Authors:  T Tervo; G B van Setten; R Andersson; E M Salonen; A Vaheri; I Immonen; A Tarkkanen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

9.  Plasmin in tear fluid of patients with corneal ulcers: basis for new therapy.

Authors:  E M Salonen; T Tervo; E Törmä; A Tarkkanen; A Vaheri
Journal:  Acta Ophthalmol (Copenh)       Date:  1987-02

10.  Elevation of tear fluid plasmin in corneal disease.

Authors:  T Tervo; E M Salonen; A Vahen; I Immonen; G B van Setten; J J Himberg; A Tarkkanen
Journal:  Acta Ophthalmol (Copenh)       Date:  1988-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.